Abstract
Ischemic Heart Disease (IHD) has been recognized as the main cause of mortality in the modern world. Application of cell therapy technologies for the IHD treatment has been actively studied from the beginning of 2000s. The review is dedicated to the use of mesenchymal stem cells (MSC) in the therapy of IHD. The strategies of the MSC modification in vitro for improvement of their regenerative potential are extensively discussed, including preconditioning to enhance the cell survival, boosting their paracrine effect and manipulating their cardiomyogenic differentiation. The optimization of the MSC delivery and opportunities related to the use of biomaterials as cell carriers are also discussed. The results of the most important clinical studies on the MSC-based IHD therapy are presented, including those completed and published in the literature and the ongoing clinical trials registered at clinicaltrials.gov by June 2018.
Keywords: Ischemic heart disease, mesenchymal stem cells, cell therapy, regenerative medicine, clinical trials, MSC-based IHD.
Current Pharmaceutical Design
Title:Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Advances and Challenges
Volume: 24 Issue: 26
Author(s): Mikhail Konoplyannikov, Svetlana Kotova*, Vladimir Baklaushev, Anatoly Konoplyannikov, Vladimir Kalsin, Peter Timashev and Alexander Troitskiy
Affiliation:
- Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow,Russian Federation
Keywords: Ischemic heart disease, mesenchymal stem cells, cell therapy, regenerative medicine, clinical trials, MSC-based IHD.
Abstract: Ischemic Heart Disease (IHD) has been recognized as the main cause of mortality in the modern world. Application of cell therapy technologies for the IHD treatment has been actively studied from the beginning of 2000s. The review is dedicated to the use of mesenchymal stem cells (MSC) in the therapy of IHD. The strategies of the MSC modification in vitro for improvement of their regenerative potential are extensively discussed, including preconditioning to enhance the cell survival, boosting their paracrine effect and manipulating their cardiomyogenic differentiation. The optimization of the MSC delivery and opportunities related to the use of biomaterials as cell carriers are also discussed. The results of the most important clinical studies on the MSC-based IHD therapy are presented, including those completed and published in the literature and the ongoing clinical trials registered at clinicaltrials.gov by June 2018.
Export Options
About this article
Cite this article as:
Konoplyannikov Mikhail , Kotova Svetlana *, Baklaushev Vladimir, Konoplyannikov Anatoly , Kalsin Vladimir , Timashev Peter and Troitskiy Alexander , Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Advances and Challenges, Current Pharmaceutical Design 2018; 24 (26) . https://dx.doi.org/10.2174/1381612824666180913151059
DOI https://dx.doi.org/10.2174/1381612824666180913151059 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis
Current Vascular Pharmacology Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design Preface
Letters in Drug Design & Discovery Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?
Current Pharmaceutical Design Achieving Better Blood Pressure Control in High-Risk Patients with Type 2 Diabetes Using Combination Antihypertensive Therapy
Vascular Disease Prevention (Discontinued) Pharmacogenetic Polymorphisms in a Portuguese Gypsy Population
Current Pharmacogenomics and Personalized Medicine Mechanistic Approach to Understanding Psychosis Risk in Velocardiofacial Syndrome
Current Pediatric Reviews Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design Uric Acid and Hypertension
Current Pharmaceutical Design Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Vascular Pharmacology Editorial: Can Statins Mitigate the Adverse Cardiovascular Effects of Smoking?
Current Vascular Pharmacology